Skip to main content

核医学市場は世界的なビジネス予測2030年に急成長しています

 


The global radiopharmaceuticals market is poised to grow at a significant pace, owing to growing demand for non-invasive techniques, availability of effective cancer treatment, and ability to observe the functioning of the organ from outside the body. Furthermore, increasing incidence of cancer & cardiovascular aliments, growing demand for alpha radio immunotherapy-based targeted cancer treatment, mounting call for nuclear imaging techniques, and advancements in radiotracers are expected to open new avenues in the radiopharmaceuticals market. Factors that are expected to drive the use of radiopharmaceuticals include changing lifestyle, elevated levels of stress, and ability to identify various diseases sooner than other diagnostic tests. However, factors such as supply volatility & logistical challenges, stringent regulatory vigil, and competition from conventional diagnostic procedures are anticipated to impede the market growth.

The global radiopharmaceuticals market is expected to garner $8,207.5 million by 2022.

Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/1131

The oncology segment contributed more than half of the market share in the overall radiopharmaceuticals market in 2015 and is expected to continue the same trend owing to perpetual rise in the number of cancer cases. The SPECT modality segment dominated the radiopharmaceuticals market in 2015, whereas the PET modality segment is anticipated to grow at a comparatively higher CAGR of 8.3% from 2016 to 2022. PET segment is driven by better quality of image and higher precision in diagnosis. Other reasons attributed to its sustained dominance are growing R&D activities especially in developing economies and widening scope of radiopharmaceutical applications such as thyroid, oncology, and bone pain palliation.

Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/1131

The Asia-Pacific radiopharmaceuticals market is expected to offer lucrative growth opportunities during the forecast period owing to aging population and increasing cancer incidences. The leading Asia-Pacific countries, such as China, Japan, and Australia would exhibit a steady growth rate.

The Major Key Players Are:

·        Mallinckrodt plc.

·        General Electric

·        Medtronic Inc.

·        Bayer AG

·        Cardinal Health Inc.

·        Lantheus Medical Imaging, Inc.

·        IBA Group

·        Bracco Imaging S.p.A.

·        NTP Radioisotopes SOC Ltd.

Key findings of Radiopharmaceuticals Market:

  • Therapeutics segment is projected to be the fastest growing segment in the radiopharmaceuticals market, registering a CAGR of 16.9% from 2016 to 2022.
  • SPECT modality segment is expected to dominate the radiopharmaceuticals market in 2015 and expected to retain its position throughout the study period.
  • Thyroid application segment is expected to exhibit double-digit CAGR of 11%.
  • Oncology application segment is expected to continue to lead the radiopharmaceuticals market, accounting for close to 60% share by 2022.
  • Asia-Pacific is projected to be the fastest growing radiopharmaceuticals market, registering a CAGR of 8.4%.

Access Full Report @ https://www.alliedmarketresearch.com/nuclear-medicine-radiopharmaceuticals-market

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

Labels:

Comments

Post a Comment

Popular posts from this blog

放射線情報システム市場 is expected to reach $941 million by 2022, supported by a CAGR of 5.9%

T he radiology information system market was valued at  $603 million  in 2015, and is projected to reach  $941 million  by 2022, growing at a CAGR of 5.9% from 2016 to 2022. The integrated radiology information systems segment held over three-fifths share of the total market in 2015. Radiology information system (RIS) is a computer networked system used to organize and manage the workflow of medical imagery and radiology department, supporting business analysis in a department. RIS is widely used along with picture archiving and communication system (PACS) and vendor neutral archive to manage billing, record keeping, and image archives. The integrated radiology information systems held the largest share in 2015 and is expected to grow at the highest CAGR of 6.0% during the analysis period. This is owing to the surging adoption and demand of integrated healthcare information technology platforms in various healthcare organization for easy operations to curb over expe...
Post a Comment
Read more

2027年までに9億8,330万ドルを獲得する心臓再同期療法市場

As per the report published by Allied Market Research, the   Cardiac Resynchronization Therapy Market   was pegged at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, growing at a CAGR of 4.9% from 2020 to 2027. Download Sample Report at:  https://www.alliedmarketresearch.com/request-sample/10657 Rise in the geriatric population, increase in the prevalence of cardiovascular diseases, and development in healthcare infrastructure have boosted the growth of the U.S. cardiac resynchronization therapy market. Moreover, high-end technological developments in CRT devices supplemented the market growth. However, product recalls in the U.S., cost of CRT devices, and shortage of healthcare professionals hinder the market growth. On the contrary, developing opportunities in the low economic U.S. states would open lucrative opportunities for the market players. Covid-19 scenario- The integration of CRT pacemaker and cardiac resynchronization therapy defibrill...
Post a Comment
Read more

組織工学市場 to Reach $6.81 Billion by 2027: Allied Market Research

As per the report published by Allied Market Research, the global  Tissue Engineering Market  generated $2.37 billion in 2019, and is projected to garner $6.81 billion by 2027, growing at a CAGR of 14.2% from 2020 to 2027. Rise in need for tissue engineering in organ transplantation, surge in prevalence of chronic diseases and trauma emergencies, and advancements in medical equipment technologies drive the growth of the global tissue engineering market. However, high cost associated with tissue engineered products hampers the market growth. On the contrary, untapped opportunities in the developing markets is expected to create lucrative opportunities in the future. Download Detailed COVID-19 Impact Sample Report at:  https://www.alliedmarketresearch.com/request-for-customization/4323?reqfor=covid Covid-19 scenario: Since the Covid-19 outbreak, clinical research in tissue engineering is temporarily suspended and the funds are redirected for clinical trials for the Covid-1...
Post a Comment
Read more